2019 Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC) – Scholarship and Grants Opportunities

    0
    426
    Opportunity ID: 310241
    Opportunity Number: CDC-RFA-CK19-1904
    Opportunity Title: 2019 Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC)
    Opportunity Category: Discretionary
    Opportunity Category Explanation:
    Funding Instrument Type: Cooperative Agreement
    Category of Funding Activity: Health
    Category Explanation:
    CFDA Number(s): 93.323
    Eligible Applicants: State governments
    County governments
    City or township governments
    Special district governments
    Others (see text field entitled “Additional Information on Eligibility” for clarification)
    Additional Information on Eligibility: Additional eligibility categories: State governments or their bona fide agents (includes the District of Columbia) Local governments or their bona fide agents Territorial governments or their bona fide agents in the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of the Northern Marianna Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau Specific ELC projects may have additional eligibility requirements associated with them. If so, these will be noted in the project-specific attachments.
    Agency Code: HHS-CDC-NCEZID
    Agency Name: Department of Health and Human Services
    Centers for Disease Control – NCEZID
    Posted Date: Nov 07, 2018
    Estimated Synopsis Post Date: Feb 11, 2019
    Fiscal Year: 2019
    Award Ceiling: $800,000,000
    Award Floor: $0
    Estimated Total Program Funding: $1,500,000,000
    Expected Number of Awards: 64
    Description: The goal of the Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC) program is to reduce illness and related deaths caused by a wide range of infectious disease threats. The ELC Program provides annual funding, strategic direction and technical assistance to domestic jurisdictions for core capacities in epidemiology, laboratory, and health information technology activities. In addition to strengthening core infectious disease capacities nationwide, this cooperative agreement also supports a myriad of specific infectious disease programs. The Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC) Notice of Funding Opportunity (NOFO) builds upon the program that was initiated in 1995 as one of the key activities under CDC’s plan to address emerging infectious disease threats. The purpose of this NOFO is to protect the public health and safety of the American people by enhancing the capacity of public health agencies to effectively detect, respond, prevent and control known and emerging (or re-emerging) infectious diseases. This is accomplished by providing financial and technical resources to (1) strengthen epidemiologic capacity; (2) enhance laboratory capacity; (3) improve information systems; and (4) enhance collaboration among epidemiology, laboratory, and information systems components of public health departments. In the last five years, NCEZID’s extramural funding has increased from $109 million in FY 2013 to $302 million in FY 2017. This increase coincides with increased responsibilities at the state and local level for emerging infectious disease control, notably for emergency responses to Ebola and Zika, and for expanded investment to curb antibiotic resistant infections and modernize public health laboratory capacity. Ebola and Zika funding began as one-time emergency funding, while AR funding is expected to reoccur annually, and base vector-borne disease funding is beginning to grow. Together with food- and water-borne disease program growth, these investments have moved from capacity building to program delivery. In other infectious disease areas, capacity building is still the focus of investments.
    Version: 1

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here